Pharvaris presents clinical data on deucrictibant, real-world HAE treatment

Pharvaris announced the presentation of two ePosters at the American College of Allergy, Asthma & Immunology 2023 Annual Scientific Meeting, being held from November 9-13, 2023 in Anaheim, CA. Prof. Marc A. Riedl, M.D., M.S., will present a poster titled “Deucrictibant immediate-release capsule reduces time to end of progression of hereditary angioedema attacks’ manifestations” on Friday, November 10, from 5:15-5:30 p.m. PST. In the phase 2 RAPIDe-1 trial, PHVS416 reduced time to the onset of symptom relief and to the resolution of HAE attacks, and substantially reduced use of rescue medication. End of progression of angioedema manifestations, which represents the first event documenting treatment response and the first evidence of attacks evolving towards relief and resolution, was assessed in a post-hoc analysis. All dose groups of PHVS416 achieved EoP at a median time of 25 or 26 minutes vs 20 hours for attacks treated with placebo. Dr. Joan Mendivil, M.D., will present a poster titled “Understanding the reasons not to treat all HAE attacks and satisfaction for on-demand treatment: physician- and patient-reported data” on Saturday, November 11, from 12:20-12:35 p.m. PST. Data detailed in the poster were drawn from the Adelphi HAE Wave II Disease Specific Program, a real-world, cross-sectional survey of people living with HAE and their treating physicians. People living with HAE reported a lower satisfaction with their current on-demand treatments than their treating physicians in terms of route of administration, discreteness to administer in public, time to resolve attacks, and ease of portability.